Safety and immunogenicity of locally produced trivalent inactivated influenza vaccine (Tri Fluvac) in healthy Thai adults aged 18-64 years in Nakhon Phanom : A Phase III double blinded, three-arm, randomized, controlled trial
Copyright © 2023. Published by Elsevier Ltd..
BACKGROUND: Domestic influenza vaccine production facilitates a sustainable supply for mitigating seasonal influenza and improves national health security by providing infrastructure and experience for pandemic vaccine production, if needed.
METHODS: A Phase III, double blind, randomized controlled trial was conducted from Sep 2019-Oct 2020 in healthy adults 18-64 years in Nakhon Phanom, Thailand. Randomization (3:3:1) compared study vaccine (Tri Fluvac), saline placebo, and an active comparator (licensed vaccine). Primary outcomes were superior efficacy compared to placebo based on RT-PCR-confirmed influenza virus infection within 12 months and non-inferiority compared to active comparator based on immunogenicity (HAI assay) at 28 days. Safety was also assessed.
RESULTS: The trial enrolled 4,284 participants (Tri Fluvac = 1,836; placebo = 1,836; active comparator = 612). There were 29 RT-PCR positive influenza infections (10 Tri Fluvac, 5.5/1,000 PY; 19 placebo, 10.4/1,000PY; 0 comparator) for an absolute protective efficacy of 46.4 (95 % CI = -22.0-76.5) compared with placebo, but the power was 43.7 %. Seroconversion difference rates between Tri Fluvac and comparator at Day 28 were 1.74 (95 % CI: -2.77, 6.25), 2.22 (-2.40, 6.84), and -0.57 (-5.41, 4.27) for A(H1N1), A(H3N2), and B strains, respectively. Adverse and severe adverse events occurred in 175 (9.5 %) Tri Fluvac, 177 (10.8 %) placebo, and 66 (10.8 %) comparator arms (p-value = 0.437, Tri Fluvac vs. comparator) CONCLUSIONS: Tri Fluvac was well tolerated, and immunogenicity was non-inferior to the active comparator, meeting U.S. Food and Drug Administration (FDA) criteria for adult vaccine licensure. Few acute respiratory infections were reported during intense COVID-19 pandemic restrictions, resulting in insufficient power to evaluate clinical efficacy.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:42 |
|---|---|
| Enthalten in: |
Vaccine - 42(2024), 1 vom: 01. Jan., Seite 24-32 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Prasert, Kriengkrai [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Adult |
|---|
| Anmerkungen: |
Date Completed 18.12.2023 Date Revised 24.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.vaccine.2023.11.050 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM36533684X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM36533684X | ||
| 003 | DE-627 | ||
| 005 | 20240424231904.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.vaccine.2023.11.050 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1385.xml |
| 035 | |a (DE-627)NLM36533684X | ||
| 035 | |a (NLM)38042698 | ||
| 035 | |a (PII)S0264-410X(23)01396-8 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Prasert, Kriengkrai |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Safety and immunogenicity of locally produced trivalent inactivated influenza vaccine (Tri Fluvac) in healthy Thai adults aged 18-64 years in Nakhon Phanom |b A Phase III double blinded, three-arm, randomized, controlled trial |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 18.12.2023 | ||
| 500 | |a Date Revised 24.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023. Published by Elsevier Ltd. | ||
| 520 | |a BACKGROUND: Domestic influenza vaccine production facilitates a sustainable supply for mitigating seasonal influenza and improves national health security by providing infrastructure and experience for pandemic vaccine production, if needed | ||
| 520 | |a METHODS: A Phase III, double blind, randomized controlled trial was conducted from Sep 2019-Oct 2020 in healthy adults 18-64 years in Nakhon Phanom, Thailand. Randomization (3:3:1) compared study vaccine (Tri Fluvac), saline placebo, and an active comparator (licensed vaccine). Primary outcomes were superior efficacy compared to placebo based on RT-PCR-confirmed influenza virus infection within 12 months and non-inferiority compared to active comparator based on immunogenicity (HAI assay) at 28 days. Safety was also assessed | ||
| 520 | |a RESULTS: The trial enrolled 4,284 participants (Tri Fluvac = 1,836; placebo = 1,836; active comparator = 612). There were 29 RT-PCR positive influenza infections (10 Tri Fluvac, 5.5/1,000 PY; 19 placebo, 10.4/1,000PY; 0 comparator) for an absolute protective efficacy of 46.4 (95 % CI = -22.0-76.5) compared with placebo, but the power was 43.7 %. Seroconversion difference rates between Tri Fluvac and comparator at Day 28 were 1.74 (95 % CI: -2.77, 6.25), 2.22 (-2.40, 6.84), and -0.57 (-5.41, 4.27) for A(H1N1), A(H3N2), and B strains, respectively. Adverse and severe adverse events occurred in 175 (9.5 %) Tri Fluvac, 177 (10.8 %) placebo, and 66 (10.8 %) comparator arms (p-value = 0.437, Tri Fluvac vs. comparator) CONCLUSIONS: Tri Fluvac was well tolerated, and immunogenicity was non-inferior to the active comparator, meeting U.S. Food and Drug Administration (FDA) criteria for adult vaccine licensure. Few acute respiratory infections were reported during intense COVID-19 pandemic restrictions, resulting in insufficient power to evaluate clinical efficacy | ||
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Clinical Trial, Phase III | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Adult | |
| 650 | 4 | |a Clinical trial | |
| 650 | 4 | |a Influenza vaccines | |
| 650 | 4 | |a Thailand | |
| 650 | 7 | |a Influenza Vaccines |2 NLM | |
| 650 | 7 | |a Vaccines, Inactivated |2 NLM | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 700 | 1 | |a Praphasiri, Prabda |e verfasserin |4 aut | |
| 700 | 1 | |a Lerdsamran, Hatairat |e verfasserin |4 aut | |
| 700 | 1 | |a Nakphook, Sutthichai |e verfasserin |4 aut | |
| 700 | 1 | |a Ditsungnoen, Darunee |e verfasserin |4 aut | |
| 700 | 1 | |a Chawalchitiporn, Sutthinan |e verfasserin |4 aut | |
| 700 | 1 | |a Sornwong, Kanlaya |e verfasserin |4 aut | |
| 700 | 1 | |a Poopipatpol, Kittisak |e verfasserin |4 aut | |
| 700 | 1 | |a Wirachwong, Ponthip |e verfasserin |4 aut | |
| 700 | 1 | |a Narakorn, Piengthong |e verfasserin |4 aut | |
| 700 | 1 | |a Surichan, Somchaiya |e verfasserin |4 aut | |
| 700 | 1 | |a Suthepakul, Nava |e verfasserin |4 aut | |
| 700 | 1 | |a Thangsupanimitchai, Napawan |e verfasserin |4 aut | |
| 700 | 1 | |a Pittayawonganon, Chakrarat |e verfasserin |4 aut | |
| 700 | 1 | |a Puthavathana, Pilaipan |e verfasserin |4 aut | |
| 700 | 1 | |a Davis, William W |e verfasserin |4 aut | |
| 700 | 1 | |a Mott, Joshua A |e verfasserin |4 aut | |
| 700 | 1 | |a Olsen, Sonja J |e verfasserin |4 aut | |
| 700 | 1 | |a Patumanond, Jayanton |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Vaccine |d 1985 |g 42(2024), 1 vom: 01. Jan., Seite 24-32 |w (DE-627)NLM012600105 |x 1873-2518 |7 nnns |
| 773 | 1 | 8 | |g volume:42 |g year:2024 |g number:1 |g day:01 |g month:01 |g pages:24-32 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.vaccine.2023.11.050 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 42 |j 2024 |e 1 |b 01 |c 01 |h 24-32 | ||